Paper Review Records
All Paper Review Records
24 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
CLDN6 defines a liver-metastatic CMS4 subgroup in colorectal cancer via CLDN6–SRC–FOXO1 signaling and epigenetic reprogramming
Rui Li; Yaoyao Zhou; Qingwu Du; Wenxia Zhao; Shihui Cao; Bo Ni; Ziyun Liu; Chao Liu; Feng Liu; Jie Zhang; Yongjie Xie; Yamei Han; Chunnuan WuShow moreShow less
1. Department of Biochemistry and Molecular Biology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, Tianjin, China; 2. Tianjin’s Clinical Research Center for Cancer, Tianjin, Tianjin, China; 3. Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin, China; 4. Department of Laboratory, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, Tianjin, China; 5. Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Henan, Zhengzhou, China; 6. Institute of Cancer Research, Henan Academy of Innovations in Medical Science, Henan, Zhengzhou, China; 7. Department of Pharmacy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, Tianjin, China; 8. Pancreas Center, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, Tianjin, China; 9. State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin, Tianjin, China; 10. Tianjin Key Laboratory of Digestive Cancer, Tianjin, Tianjin, China; 11. Department of Head and Neck Oncology, Cancer Institute & Hospital, Tianjin Medical University, National Clinical Research Center for Cancer, Tianjin, Tianjin, China; 12. Department of Equipment and Materials, Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, ChinaShow moreShow less
Redirecting expanded effector lymphocytes with engineered HER2 antibodies extends therapeutic sensitivity in HER2-non-amplified and trastuzumab-refractory breast cancer
Hieu Trong Ngo; Elisa Cappuzzello; Pierangela Palmerini; Emilia Vigolo; Giulia D’Accardio; Lorenzo Nicolè; Gaia Griguolo; Valentina Guarneri; Steffen Krohn; Matthias Peipp; Antonio Rosato; Roberta SommaggioShow moreShow less
1. Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy; 2. Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy; 3. Department of Pathology, Angelo’s Hospital, Venice, Italy; 4. Medical Oncology 2, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy; 5. Division of Antibody-Based Immunotherapy, Department of Internal Medicine II, University Hospital Schleswig-Holstein and Christian-Albrechts- University Kiel, Kiel, GermanyShow moreShow less
GLOBO H targeting CAR T Cells: generation and preclinical activity in gastrointestinal cancer cell lines
Francesca Putti; Marco Gentili; Luca Roz; Elena Luison; Davide Tresoldi; Paolo Cappella; Marco Barella; Chiara C. Volpi; Licia Rivoltini; Giancarlo Pruneri; Filippo de Braud; Mariangela Figini; Francesca De Santis; Massimo Di NicolaShow moreShow less
1. Unit of Immunotherapy and Anticancer Innovative Therapeutics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 2. Epigenomics and biomarkers of solid tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; 3. ANP, Department of Advanced Diagnostics, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy; 4. Unit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 5. Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 6. Department of Oncology and Hemato-Oncology, University of Milan, Milan, ItalyShow moreShow less
NAT10-mediated acetylation of JunB drives melanoma progression by enforcing SLC27A1-dependent lipid metabolic reprogramming
Jianlan Liu; Bo Wang; Yurong Liu; Baogen Du; Xiaolong Cheng; Pengpeng Zhang; Xiaojian Cao; Shouyu Wang; Jian TangShow moreShow less
1. Department of Hepatobiliary Surgery,The First Affiliated Hospital of Anhui Medical University; MOE Innovation Center for Basic Research in Tumor Immunotherapy; Anhui Province KeyLaboratory of Tumor Immune Microenvironment and Immunotherapy, Hefei, China; 2. Department of Plastic and Burns Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; 3. Department of Neurology, The Third Affiliated Hospital of Anhui Medical University, The First People’s Hospital of Hefei, Hefei, China; 4. Department of Lung Cancer, Tianjin Lung Cancer Center, Key Laboratory of Cancer Preventionand Therapy, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center forCancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; 5. Department of Orthopedics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaShow moreShow less
Development of gemcitabine-modified miR-15a as a novel, multimodal treatment strategy to overcome 5-FU and oxaliplatin resistance in colorectal cancer
Anushka Ojha; Amartya Pal; Max Chao; Ramana V Davuluri; Jingfang JuShow moreShow less
1. Department of Pathology, Renaissance School of Medicine, Stony Brook University, Stony Brook, USA; 2. Graduate Program in Molecular and Cellular Biology, Stony Brook University, Stony Brook, USA; 3. Department of Biomedical Informatics, Stony Brook Cancer Centre, Stony Brook University, Stony Brook, USA; 4. The Northport Veteran’s Administration Medical Center, Northport, USAShow moreShow less
ERG inhibition selectively sensitizes ERG-positive prostate cancer to radiation through DNA repair vulnerabilities and enhances response to androgen receptor inhibitors
Ayham Moustafa; Mohamed E. Elsesy; Bente Siebels; Jan Hahn; Su-Jung Oh-Hohenhorst; Carlotta Schudy; Thorsten Rieckmann; Susanne Burdak-Rothkamm; Derya Tilki; Tobias Maurer; Cordula Petersen; Kai Rothkamm; Gunhild von Amsberg; Carsten Bokemeyer; Hartmut Schlüter; Sabrina Köcher; Wael Y. MansourShow moreShow less
1. Department of Radiotherapy and Radiooncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 2. Mildred Scheel Cancer Career Center HaTriCS4, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 3. Section of Mass Spectrometric Proteomics, University Medical Center Hamburg Eppendorf, Hamburg, Germany; 4. Pharmacology and Experimental Oncology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt; 5. Martini-Klinik Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 6. Department of Otorhinolaryngology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 7. Department of Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK; 8. Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; 9. Department of Urology, Koc University Hospital, Istanbul, Türkiye; 10. Department of Oncology, II Med. Klinik, Hematology, BMT With Section Pneumology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyShow moreShow less
FAQ
How long does JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH take to review a manuscript?
As of 2026-11-18, CrushSCI has 24 complete review records for JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. The fastest paper went from submission to acceptance in 11 days (Transcriptional evidence of neuroendocrine cell plasticity beyond histological boundaries in lung neuroendocrine neoplasms: an in-silico analysis suggesting a progression model, received 2026-07-08, accepted 2026-07-19); the slowest took 221 days. The average is 139.4 days and the median is 142.5 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
